Core Financials & Fund Structure:
- The Anchor Investor: Novo Holdings (the controlling entity of obesity drugmaker Novo Nordisk) has committed 500 million euros ($582 million) as a founding investor in the newly launched Scaleup Europe Fund.
- Fund Size Targets: The pan-European tech growth vehicle is targeting a total size of 5 billion euros, with a hard cap set at 6–7 billion euros.
- Check Sizes: The fund will focus on growth, late-stage growth, and pre-IPO phases across Europe, deploying typical investment sizes of more than 100 million euros per deal (including follow-ons).
- Timeline: Final legal documentation and operational setups are being concluded, with the first investments officially expected to deploy starting in autumn 2026.
Strategic Mandate & Backers:
- The Coalition: The fund unites a prominent group of European public and institutional founding investors, including the European Commission, Novo Holdings, EIFO (Export and Investment Fund of Denmark), CriteriaCaixa, Santander, and Allianz.
- Core Themes: Capital will be allocated across three broad structural pillars: digital and intelligent systems, physical systems, and human/planetary health.
- The Objective: The overarching goal of the initiative is to pool long-term capital to scale domestic innovation, helping strategic tech companies grow while ensuring they remain anchored within Europe.